###begin article-title 0
###xml 6 10 <span type="species:ncbi:10090">Mice</span>
Obese Mice Lacking Inducible Nitric Oxide Synthase Are Sensitized to the Metabolic Actions of Peroxisome Proliferator-Activated Receptor-gamma Agonism
###end article-title 0
###begin p 1
###xml 41 71 41 71 <email xmlns:xlink="http://www.w3.org/1999/xlink">andre.marette@crchul.ulaval.ca</email>
Corresponding author: Dr. Andre Marette, andre.marette@crchul.ulaval.ca
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
###xml 420 424 <span type="species:ncbi:10090">mice</span>
OBJECTIVE-Synthetic ligands for peroxisome proliferator-activated receptor-gamma (PPAR-gamma) improve insulin sensitivity in obesity, but it is still unclear whether inflammatory signals modulate their metabolic actions. In this study, we tested whether targeted disruption of inducible nitric oxide (NO) synthase (iNOS), a key inflammatory mediator in obesity, modulates the metabolic effects of rosiglitazone in obese mice.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 32 35 32 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 44 47 44 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
RESEARCH DESIGN AND METHODS-iNOS-/- and iNOS+/+ were subjected to a high-fat diet or standard diet for 18 weeks and were then treated with rosiglitazone for 2 weeks. Whole-body insulin sensitivity and glucose tolerance were determined and metabolic tissues harvested to assess activation of insulin and AMP-activated protein kinase (AMPK) signaling pathways and the levels of inflammatory mediators.
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 149 152 149 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 167 170 167 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 546 549 546 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 631 634 627 630 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
###xml 277 281 <span type="species:ncbi:10090">mice</span>
###xml 550 554 <span type="species:ncbi:10090">mice</span>
###xml 635 639 <span type="species:ncbi:10090">mice</span>
RESULTS-Rosiglitazone was found to similarly improve whole-body insulin sensitivity and insulin signaling to Akt/PKB in skeletal muscle of obese iNOS-/- and obese iNOS+/+ mice. However, rosiglitazone further improved glucose tolerance and liver insulin signaling only in obese mice lacking iNOS. This genotype-specific effect of rosiglitazone on glucose tolerance was linked to a markedly increased ability of the drug to raise plasma adiponectin levels. Accordingly, rosiglitazone increased AMPK activation in muscle and liver only in obese iNOS-/- mice. PPAR-gamma transcriptional activity was increased in adipose tissue of iNOS-/- mice. Conversely, treatment of 3T3-L1 adipocytes with a NO donor blunted PPAR-gamma activity.
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
CONCLUSIONS-Our results identify the iNOS/NO pathway as a critical modulator of PPAR-gamma activation and circulating adiponectin levels and show that invalidation of this key inflammatory mediator improves the efficacy of PPAR-gamma agonism in an animal model of obesity and insulin resistance.
###end p 6
###begin p 7
Published ahead of print at  on 5 May 2008.
###end p 7
###begin p 8
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 365 366 353 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 543 544 531 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 860 861 844 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 862 863 846 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 1080 1081 1064 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 1082 1083 1066 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 1208 1209 1192 1193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 1210 1211 1194 1195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 1350 1351 1334 1335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is a member of the ligand-activated nuclear receptor family, which is highly expressed in adipose tissues, where it promotes adipocyte differentiation and lipid storage. PPAR-gamma can be activated by several endogenous lipid ligands and is a known target of the antidiabetic agents thiazolidinediones (1). Thiazolidinediones are known for their lipid-lowering and insulin-sensitizing actions and are currently used to manage obesity-linked insulin resistance and type 2 diabetes (2). Although the molecular mechanism of action of thiazolidinedione/PPAR-gamma ligands on glucose and lipid metabolism is not fully understood, their ability to increase plasma levels of adiponectin, an adipose-specific secretory protein, is thought to be involved in their metabolic and insulin-sensitizing actions (3-5). Adiponectin circulates as both a hexamer and a high-molecular weight oligomer. The latter complex form mediates the effects of thiazolidinediones on insulin sensitivity, particularly on hepatic glucose production (5-8). The insulin-sensitizing activity of adiponectin appears to involve the activation of AMP-activated protein kinase (AMPK) (4,6), a metabolic sensor that has been reported to alleviate obesity-driven insulin resistance through metabolic and gene expression effects (9).
###end p 9
###begin p 10
###xml 313 315 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 316 318 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 715 717 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 718 720 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 876 878 852 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 879 881 855 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 1010 1012 986 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 1013 1015 989 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 1281 1283 1257 1259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 1284 1286 1260 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 1551 1553 1527 1529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 1693 1695 1669 1671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 1751 1756 1727 1732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ob/ob</italic>
###xml 1763 1765 1739 1741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 1766 1768 1742 1744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 1868 1870 1844 1846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 1871 1873 1847 1849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 1950 1952 1926 1928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 1967 1969 1943 1945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 1196 1199 <span type="species:ncbi:10116">rat</span>
###xml 1545 1549 <span type="species:ncbi:10090">mice</span>
###xml 1757 1761 <span type="species:ncbi:10090">mice</span>
Anti-inflammatory mechanisms may also contribute to the beneficial action of PPAR-gamma activation on insulin sensitivity. Obesity is a state of abnormal inflammatory response, leading to increased production of proinflammatory cytokines, which are thought to promote insulin resistance in key metabolic tissues (10,11). Activation of PPAR-gamma opposes the effects of proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha), and negatively interferes with cytokine-inducible transcriptional pathways (e.g., nuclear factor-kappaB [NF-kappaB], signal transducer and activator of transcription [STAT], and activator protein 1 [AP-1]) in adipocytes, macrophages, and other vascular wall cell types (12-15). Thiazolidinediones inhibit the expression of inducible nitric oxide (NO) synthase (iNOS), a key inflammatory mediator in several cell types and tissues (16,17). iNOS expression is increased in insulin-target tissues and pancreatic islets of animal models of dietary and genetic obesity (18-20). We have previously reported that proinflammatory cytokines and the endotoxin lipopolysaccharide (LPS) induce iNOS expression and marked NO production in L6 myocytes and isolated rat skeletal muscles, leading to defective insulin stimulation of glucose transport (21,22). A key role for iNOS in the pathogenesis of obesity-linked insulin resistance is supported by our previous observations that targeted disruption of iNOS protects against muscle insulin resistance and improves whole-body insulin action in high-fat-fed obese mice (18). More recently, iNOS disruption was also found to protect against the adverse effects of high-fat feeding on vascular insulin resistance (23) and to reduce insulin resistance in genetically obese ob/ob mice (24,25). Furthermore, iNOS is induced in skeletal muscle and adipose tissues of type 2 diabetic subjects (26,27) where its expression correlates with the occurrence of insulin resistance (27) and obesity (26).
###end p 10
###begin p 11
###xml 223 225 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 987 991 <span type="species:ncbi:10090">mice</span>
Whereas thiazolidinedione-mediated PPAR-gamma activation reduces iNOS expression in several tissues, there is also evidence suggesting that activation of the iNOS/NO pathway can blunt PPAR-gamma activation. Shibuya et al. (28) have shown that peroxynitrite, an oxidative NO derivative, inhibits ligand-dependent nuclear translocation of PPAR-gamma in macrophages, possibly through peroxynitrite-mediated nitration of PPAR-gamma. This suggests that the iNOS/NO pathway modulates PPAR-gamma activity, at least in myeloid cells. However, the potential role of the iNOS/NO pathway in the modulation of thiazolidinedione/PPAR-gamma action in key insulin-target tissues of an animal model of obesity and iNOS induction has not yet been investigated. Here, we have tested the hypothesis that iNOS modulates PPAR-gamma activity in insulin-target tissues by investigating the metabolic and glucoregulatory effects of the thiazolidinedione rosiglitazone in both wild-type and iNOS-deficient obese mice. The results identify iNOS as a critical modulator of thiazolidinedione actions in obesity.
###end p 11
###begin title 12
RESEARCH DESIGN AND METHODS
###end title 12
###begin title 13
Antibodies.
###end title 13
###begin p 14
###xml 551 552 547 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 553 555 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 0 6 <span type="species:ncbi:9986">Rabbit</span>
###xml 238 244 <span type="species:ncbi:9986">Rabbit</span>
###xml 292 298 <span type="species:ncbi:9986">rabbit</span>
###xml 478 484 <span type="species:ncbi:9986">Rabbit</span>
###xml 558 563 <span type="species:ncbi:10090">Mouse</span>
###xml 708 713 <span type="species:ncbi:10090">Mouse</span>
###xml 780 786 <span type="species:ncbi:9986">Rabbit</span>
###xml 857 861 <span type="species:ncbi:9925">Goat</span>
###xml 867 872 <span type="species:ncbi:10090">mouse</span>
###xml 881 885 <span type="species:ncbi:9925">goat</span>
###xml 891 897 <span type="species:ncbi:9986">rabbit</span>
Rabbit polyclonal antibodies against P-Ser473 Akt, P-Ser79 acetyl-CoA carboxylase (ACC), and P-Thr172-AMPK were purchased from Cell Signaling Technology (Beverly, MA) and were used at a 1:500, 1:1,000, and 1:1,000 dilution, respectively. Rabbit polyclonal iNOS, p85, and IRS-2 antibodies and rabbit monoclonal P-Ser82-PPAR-gamma antibody were purchased from Upstate Biotechnology (Lake Placid, NY) and were used at a 1:500, 1:1,000, 1:1,000, and 1:1,000 dilution, respectively. Rabbit polyclonal adiponectin antibody was used as previously described (4,29). Mouse monoclonal PPAR-gamma and P-Tyr (PY20) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and used at a 1:1,000 dilution. Mouse monoclonal alpha-tubulin antibody was from Sigma (St. Louis, MO). Rabbit anti-RFP antibody (Rockland, Gilbertsville, PA) was used at 1:10,000. Goat anti-mouse IgG and goat anti-rabbit IgG secondary antibodies were purchased from GE Healthcare (Baie d'Urfe, Quebec, Canada) and used at a 1:10,000 dilution.
###end p 14
###begin title 15
Animals and treatment.
###end title 15
###begin p 16
###xml 172 178 172 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink">tm1Lau</sup>
###xml 706 708 706 708 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 714 716 714 716 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 120 124 <span type="species:ncbi:10090">mice</span>
###xml 154 158 <span type="species:ncbi:10090">mice</span>
###xml 257 261 <span type="species:ncbi:10090">mice</span>
###xml 441 446 <span type="species:ncbi:10090">Mouse</span>
###xml 515 519 <span type="species:ncbi:10090">mice</span>
###xml 701 706 <span type="species:ncbi:10090">mouse</span>
This study was approved by the Animal Care and Handling Committee of Laval University. Breeding pairs of iNOS wild-type mice (C57BL/6J) and iNOS knockout mice (C57BL/6-NOS2tm1Lau) were purchased from The Jackson Laboratories (Bar Harbor, ME). Four-week-old mice were fed either a ground autoclaved standard chow diet (Sterilizable Global Rodent; Harlan Teklad, Madison, WI) or an irradiated high-fat diet (55% of calories derived from fat) (Mouse 9F; Test Diet, Oakville, Ontario, Canada) for 18 weeks. Half of the mice in each dietary cohort were then randomly assigned to a 15-day treatment with rosiglitazone (30 mg/kg diet as a food admixture; Avandia; GlaxoSmithKline), corresponding to 0.1 mg . mouse-1 . day-1. This dose of rosiglitazone is relatively low compared with most studies (0.4-3 mg/day) because it was designed to test for potential sensitization of rosiglitazone effects by iNOS gene disruption.
###end p 16
###begin title 17
Glucose and insulin tolerance test.
###end title 17
###begin p 18
###xml 85 89 85 89 <sc xmlns:xlink="http://www.w3.org/1999/xlink">a.m.</sc>
###xml 60 64 <span type="species:ncbi:10090">mice</span>
###xml 170 175 <span type="species:ncbi:9606">human</span>
Twelve days after the beginning of rosiglitazone treatment, mice were fasted at 8:00 a.m. for 5 h and were injected with 1 g/kg i.p. glucose or 1.5 units/kg i.p. regular human insulin (Humulin R; Lilly). Blood samples were collected from the tail vein at time 0 (before injection), 15, 30, 60, and 90 min after glucose or insulin injection, and blood glucose level was estimated with an Elite glucometer (Bayer, Etobicoke, Ontario, Canada).
###end p 18
###begin title 19
Indirect calorimetry and body composition determinations.
###end title 19
###begin p 20
###xml 38 39 38 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 128 129 128 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V</italic>
###xml 129 130 129 130 <sc xmlns:xlink="http://www.w3.org/1999/xlink">o</sc>
###xml 130 131 130 131 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 161 162 161 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V</italic>
###xml 163 164 163 164 <sc xmlns:xlink="http://www.w3.org/1999/xlink">o</sc>
###xml 164 165 164 165 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 423 425 423 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 431 433 431 433 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 18 22 <span type="species:ncbi:10090">mice</span>
###xml 222 226 <span type="species:ncbi:10090">Mice</span>
###xml 418 423 <span type="species:ncbi:10090">mouse</span>
###xml 772 776 <span type="species:ncbi:10090">mice</span>
Randomly selected mice of each group (n = 6 per group) in a subset were individually monitored to determine oxygen consumption (Vo2), carbon dioxide production (Vco2), and the respiratory quotient by indirect calorimetry. Mice were initially placed in their individual metabolic cage for 2 days before the beginning of the experiment. Measurements were made continuously during the following 2 days (36 measurements . mouse-1 . day-1) in an open circuit system with an oxygen analyzer (S-3A1; Applied Electrochemistry) and a carbon dioxide analyzer (CD-3A; Applied Electrochemistry). Data presented are the average of all measurements made over 2 days of monitoring. Dual X-ray absorptiometry (Piximus; Lunar, Madison, WI) was used to measure total fat and lean masses in mice anesthetized with isoflurane.
###end p 20
###begin title 21
Acute insulin injection and death.
###end title 21
###begin p 22
###xml 410 411 409 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 245 249 <span type="species:ncbi:10090">mice</span>
Mice were anesthetized with isoflurane, and blood sampling (150-200 mul) from the orbital sinus was performed for later plasma analysis. An acute injection of 3.8 units/kg i.v. insulin (Humulin R; Lilly) was then performed in the tail vein, and mice were killed by decapitation 4 min after injection. Tissues were then rapidly excised and frozen in liquid nitrogen. Blood was collected and centrifuged at 3,000g for 10 min at 4degreesC to isolate plasma. Plasma and tissues were stored at -80degreesC until biochemical analysis.
###end p 22
###begin title 23
Islet isolation and insulin secretion measurements.
###end title 23
###begin p 24
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 784 786 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
Pancreatic islets were harvested and cultured for 2 h before initiating insulin secretion as described previously (30). Briefly, islets were distributed in batches of 10 with four replicates for each condition per genotype. Islets were washed and preincubated for 45 min at 37degreesC in Krebs-Ringer bicarbonate buffer containing 10 mmol/l HEPES (KRBH, pH 7.4) with 0.5% defatted BSA (Sigma) and 3 mmol/l glucose. The islets were then incubated for 1 h at 37degreesC in KRBH containing 3, 8, or 16 mmol/l glucose and 0.5% BSA. Some experiments were also performed in the absence or presence of 0.4 mmol/l palmitate during the incubation. At the end of the incubation, media were withdrawn for insulin determination, and islets were harvested for assessment of total insulin content (30).
###end p 24
###begin title 25
Adipose tissue histology.
###end title 25
###begin p 26
###xml 384 385 383 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Tissues were fixed in 10% buffered formalin and embedded in paraffin. Multiple 10-mum sections were obtained from epididymal white adipose tissue (WAT) and stained with hematoxylin-eosin. Images were acquired using a BX60 microscope (Olympus, NY) and an RT slider 2.3.0 camera (Diagnostic Instrument, Sterling Heights, MI) and were analyzed using SPOT 4.0.2 software. For each group (n = 6), at least four fields, representing 300 adipocytes per slide, were analyzed, and the geometric mean of adipocyte diameter was calculated to estimate adipocyte mass. Cellularity was calculated as the ratio of epididymal tissue mass to mean adipocyte mass.
###end p 26
###begin title 27
RNA extraction and RT-PCR.
###end title 27
###begin p 28
###xml 161 163 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 164 166 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
Fifty milligrams of WAT was used to isolate total RNA using Trizol reagent (Invitrogen), and iNOS and beta-actin mRNAs were measured by semiquantitative RT-PCR (18,21). For PCR, 50 ng each of the following primer pairs was used: iNOS, 5'-CAG CCT CAG AGT CCT TCA TG-3' (forward) and 5'-GGT GCT TGC CTT ATA CTG GTC-3' (reverse); and beta-actin, 5'-TCA CCC ACA CTG TGC CCA TCT ACG A-3' (forward) and 5'-GGA TGC CAC AGG ATT CCA TAC CCA-3' (reverse). Amplification products were run in 8% acrylamide gel or 1.5% agarose gel containing 1 mug/ml ethidium bromide and analyzed under UV illumination.
###end p 28
###begin title 29
Protein extraction, immunoprecipitation, and Western blotting.
###end title 29
###begin p 30
###xml 278 279 278 279 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 294 295 294 295 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 355 356 355 356 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 358 359 358 359 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 620 621 613 614 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 623 624 616 617 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 869 871 861 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 872 874 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 1094 1100 <span type="species:ncbi:10090">murine</span>
Fifty milligrams of quadriceps muscle, WAT, and liver tissues were pulverized with a pestle and mortar in liquid nitrogen, and the powder was homogenized in 6 vol (muscle and liver) or 4 vol (WAT) homogenization buffer (20 mmol/l Tris-HCl, pH 7.5, 150 mmol/l NaCl, 1 mmol/l CaCl2, 1 mmol/l MgCl2, 10% glycerol, 1% Igepal CA-630, 10 mmol/l NaF, 2 mmol/l Na3VO4, 1 mmol/l phenylmethylsulfonyl fluoride, and protease inhibitors). One milligram of proteins was immunoprecipitated overnight at 4degreesC with 2 mug PY20. Immune complexes were washed three times with PBS containing 1% Nonidet P-40, 10 mmol/l NaF, 2 mmol/l Na3VO4, and protease inhibitors. For Western blot analysis, 10-50 mug crude protein lysates or immune complexes were solubilized in sample buffer, loaded on a 7.5% acrylamide gel and subjected to SDS-PAGE and Western blotting as previously described (21,22). Bands were detected by standard chemiluminescence (Perkin Elmer) and were scanned for quantification using Image J software. Adipose tissue lysates were analyzed for TNF-alpha and interleukin-6 (IL-6) content using a murine ELISA kit (BD Biosciences, Mississauga, Ontario, Canada).
###end p 30
###begin title 31
Plasma hormones and adipokines.
###end title 31
###begin p 32
###xml 446 447 446 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 448 449 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 79 84 <span type="species:ncbi:10090">mouse</span>
Plasma leptin, insulin, adiponectin, and resistin levels were determined using mouse radioimmunoassay kits as recommended by the manufacturer (Linco Research, St. Charles, MO). Insulin levels during glucose tolerance test (GTT) were determined using a mammal ELISA kit (Alpco Diagnostics, Salem, NH). Different molecular weight adiponectin complexes were separated by velocity sedimentation/gel filtration chromatography as previously described (5,7).
###end p 32
###begin title 33
PPAR-gamma expression, phosphorylation, and transcriptional activity.
###end title 33
###begin p 34
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 410 412 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 413 415 413 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 416 418 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 57 65 <span type="species:ncbi:9606">Children</span>
###xml 1034 1045 <span type="species:ncbi:3704">horseradish</span>
###xml 1334 1339 <span type="species:ncbi:10090">mouse</span>
3T3-L1 cells, provided by Dr. A. Klip (Hopsital for Sick Children, Toronto, Canada) were grown and differentiated as previously described (17). Fully differentiated 3T3-L1 adipocytes were treated with sodium nitroprusside (Sigma) or peroxynitrite (Upstate) for 24 h. Cell culture supernatants were collected, and nitrite levels were determined as an indirect measurement of NO production by the Griess method (17,21,22). Cell lysates were used for determination of PPAR-gamma expression and Ser-82 phosphorylation. Nuclear extracts were prepared, and 10 mul was analyzed for PPAR-gamma-specific transcription factor binding activity as described by the manufacturer (Cayman, Ann Arbor, MI). In brief, nuclear extracts were loaded on a 96-well plate coated with a double-stranded DNA sequence containing the peroxisome proliferator response element. After 16-h incubation at 4degreesC, the plates were washed, and a primary antibody directed against PPAR-gamma was added for 1 h at room temperature. A secondary antibody conjugated to horseradish peroxidase was added to provide a sensitive colorometric readout at 450 nm. The results were corrected for total protein content in 10 mul nuclear extract. HEK293T cells were provided by Dr. J. Lavoie (Centre de Recherche en Cancerologie, Quebec, Canada). The cells were transfected with mouse PPAR-gamma2 and pGL3-PPRE (provided by Dr. F. Picard, Hopital Laval, Quebec, Canada) and pmRFP-N1 (provided by Dr. J. Lavoie) using calcium phosphate. Twenty-four hours after transfection, cells were treated with sodium nitroprusside or peroxynitrite for 8 h followed by addition of 20 mumol/l troglitazone for 16 h. Cell lysates were analyzed for luciferase activity and corrected for expression of RFP by Western blot by scanning and quantification.
###end p 34
###begin title 35
Data presentation and statistical analysis.
###end title 35
###begin p 36
###xml 151 154 149 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 460 463 458 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 469 472 467 470 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 965 966 963 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Data are expressed as means +/- SE. Except for basal physiological parameters, only data from the high-fat diet cohorts and the chow-fed untreated iNOS+/+ group (used as a reference) are shown in the figures, because iNOS gene disruption and rosiglitazone treatments had only marginal effects in the chow-fed groups. The main effect of diet on all parameters were analyzed by a 2 x 2 x 2 factorial ANOVA test. The main and interactive effects of genotype (iNOS+/+, iNOS-/-) and treatment (untreated, rosiglitazone) were analyzed separately for each dietary cohort by a 2 x 2 factorial ANOVA test. All parameters of each dietary cohort were also analyzed separately by ANOVA. Pairwise between-group differences were identified in the high-fat-fed cohort by post hoc Fisher's protected least significant difference test. Results of the latter analysis in the high-fat-fed cohort are presented at the end of each figure legend. The level of significance was chosen as P < 0.05.
###end p 36
###begin title 37
RESULTS
###end title 37
###begin title 38
Effects of genotype, high-fat feeding, and rosiglitazone on physiological parameters.
###end title 38
###begin p 39
###xml 4 7 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 16 19 16 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 416 423 416 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 601 602 601 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 677 680 677 680 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 689 692 689 692 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 730 737 730 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 20 24 <span type="species:ncbi:10090">mice</span>
###xml 149 153 <span type="species:ncbi:10090">mice</span>
###xml 240 244 <span type="species:ncbi:10090">mice</span>
###xml 467 471 <span type="species:ncbi:10090">mice</span>
###xml 519 523 <span type="species:ncbi:10090">mice</span>
###xml 595 599 <span type="species:ncbi:10090">mice</span>
###xml 693 697 <span type="species:ncbi:10090">mice</span>
iNOS+/+ and iNOS-/- mice were fed a standard low-fat chow diet or a high-fat diet for 18 weeks to induce obesity and insulin resistance. Half of the mice of each dietary cohort were then treated with rosiglitazone for 15 days. High-fat-fed mice of either genotype showed a similar increase in total body weight, body weight gain, and total body fat mass, and rosiglitazone treatment did not affect these parameters (Table 1). The daily caloric intake of high-fat-fed mice was, as expected, higher than that of chow-fed mice. A small increase in caloric intake was also observed in iNOS knockout mice (P = 0.03 for genotype effect), but food consumption was similar between iNOS+/+ and iNOS-/- mice during rosiglitazone treatment (Table 1).
###end p 39
###begin title 40
###xml 78 82 <span type="species:ncbi:10090">mice</span>
Rosiglitazone inhibits iNOS induction in adipose tissue of obese high-fat-fed mice.
###end title 40
###begin p 41
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 180 186 180 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 271 272 271 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 301 304 301 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 512 515 512 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 68 72 <span type="species:ncbi:10090">mice</span>
###xml 117 121 <span type="species:ncbi:10090">mice</span>
###xml 305 309 <span type="species:ncbi:10090">mice</span>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
###xml 446 450 <span type="species:ncbi:10090">mice</span>
###xml 516 520 <span type="species:ncbi:10090">mice</span>
We have previously shown that iNOS is induced in high-fat-fed obese mice (18). iNOS induction in WAT of high-fat-fed mice was confirmed by RT-PCR and Western blot analysis of WAT (Fig. 1). We found that both iNOS mRNA and protein levels were increased two- to threefold (P < 0.05) in WAT of obese iNOS+/+ mice compared with control chow-fed mice. Rosiglitazone treatment completely normalized iNOS expression levels to those observed in chow-fed mice. As expected, iNOS expression was not detected in WAT of iNOS-/- mice.
###end p 41
###begin title 42
###xml 33 37 <span type="species:ncbi:10090">mice</span>
iNOS disruption sensitizes obese mice to the beneficial effect of rosiglitazone on glucose tolerance.
###end title 42
###begin p 43
###xml 110 113 110 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 122 125 122 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 179 186 179 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 331 334 331 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 357 360 357 360 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 431 432 431 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 126 130 <span type="species:ncbi:10090">mice</span>
###xml 246 250 <span type="species:ncbi:10090">mice</span>
###xml 361 365 <span type="species:ncbi:10090">mice</span>
After 18 weeks of high-fat feeding, fasting blood glucose and insulin levels were increased in both obese iNOS+/+ and iNOS-/- mice compared with their lean chow-fed counterparts (Table 1). Rosiglitazone was found to reduce hyperglycemia in obese mice of both genotypes. Hyperinsulinemia was decreased by rosiglitazone in obese iNOS+/+, but not in obese iNOS-/- mice, because iNOS disruption per se tended to reduce insulin levels (P = 0.08). A significant effect of iNOS gene disruption was also observed on plasma leptin and triglyceride levels (2 x 2 ANOVA test).
###end p 43
###begin p 44
###xml 201 204 201 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 242 245 242 245 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 258 259 258 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 260 261 260 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 252 261 252 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic>&#8211;<italic>D</italic></xref>
###xml 410 411 410 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 404 411 404 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 494 495 494 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 488 495 488 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 571 574 571 574 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 732 733 732 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 738 739 738 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 726 739 726 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>C</italic> and <italic>D</italic></xref>
###xml 835 836 835 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 841 842 841 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 829 842 829 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>C</italic> and <italic>D</italic></xref>
###xml 908 911 908 911 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 920 923 920 923 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 969 970 969 970 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 963 970 963 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>E</italic></xref>
###xml 1011 1012 1011 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1156 1157 1156 1157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1192 1195 1192 1195 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1246 1249 1246 1249 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1262 1263 1262 1263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1256 1263 1256 1263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>F</italic></xref>
###xml 205 209 <span type="species:ncbi:10090">mice</span>
###xml 246 250 <span type="species:ncbi:10090">mice</span>
###xml 575 579 <span type="species:ncbi:10090">mice</span>
###xml 673 677 <span type="species:ncbi:10090">mice</span>
###xml 810 814 <span type="species:ncbi:10090">mice</span>
###xml 924 928 <span type="species:ncbi:10090">mice</span>
###xml 1196 1200 <span type="species:ncbi:10090">mice</span>
###xml 1250 1254 <span type="species:ncbi:10090">mice</span>
The effect of rosiglitazone on whole-body insulin sensitivity and glucose tolerance was next examined in both genotypes. High-fat feeding caused insulin resistance and glucose intolerance in obese iNOS+/+ mice compared with lean chow-fed iNOS+/+ mice (Fig. 2A-D). Insulin sensitivity was independently improved by both iNOS disruption and rosiglitazone treatment as revealed by insulin tolerance curves (Fig. 2A) and the average reduction in blood glucose 15 min after insulin injection (Fig. 2B). Rosiglitazone failed to further enhance insulin sensitivity in obese iNOS-/- mice. In contrast, neither iNOS disruption nor rosiglitazone treatment alone was found to protect mice from high-fat diet-induced glucose intolerance (Fig. 2C and D). However, rosiglitazone markedly improved glucose tolerance in obese mice lacking iNOS (Fig. 2C and D). Insulin levels during the GTT was elevated in high-fat-fed iNOS+/+ and iNOS-/- mice compared with the chow-fed group (Fig. 2E). Rosiglitazone reduced insulin levels (P < 0.05) but not when combined with iNOS gene disruption. Glucose-stimulated insulin secretion (GSIS) in freshly isolated islets was increased (P < 0.05) in high-fat-fed obese iNOS+/+ mice compared with islets from lean chow- fed iNOS+/+ mice (Fig. 2F). This effect was only observed at the highest dose of glucose tested. GSIS was affected neither by iNOS genetic deletion nor by rosiglitazone treatment. GSIS by isolated islets was also similar in the presence of palmitate during the incubations (data not shown).
###end p 44
###begin title 45
###xml 95 99 <span type="species:ncbi:10090">mice</span>
iNOS disruption increases insulin signaling to Akt/PKB in liver of rosiglitazone-treated obese mice.
###end title 45
###begin p 46
###xml 82 85 82 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 94 97 94 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 329 335 329 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3</xref>
###xml 408 409 408 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 402 409 402 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 428 429 428 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 422 429 422 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 901 902 901 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 895 902 895 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 1090 1093 1090 1093 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1170 1171 1170 1171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1164 1171 1164 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
###xml 583 587 <span type="species:ncbi:10090">mice</span>
The effect of rosiglitazone on insulin action in skeletal muscle and liver of iNOS+/+ and iNOS-/- mice was then assessed by measurement of insulin-mediated Ser-473 phosphorylation of Akt/PKB, a key effector of insulin-induced inhibition of hepatic glucose production and stimulation of muscle glucose uptake (31). As depicted in Fig. 3, high-fat feeding caused a profound insulin resistance in muscle (Fig. 3A) and liver (Fig. 3B), as demonstrated by a 50 and 75% reduction in insulin-stimulated Akt/PKB phosphorylation, respectively, compared with the effect of insulin in chow-fed mice (dashed lines). As previously observed for whole-body insulin sensitivity (insulin tolerance test), rosiglitazone treatment and iNOS deficiency both independently corrected defective insulin-induced Akt/PKB activation in muscle, but their combination did not further increase insulin action in that tissue (Fig. 3A). Conversely, in liver, neither rosiglitazone nor iNOS gene disruption alone was found to improve insulin-stimulated Akt/PKB phosphorylation, whereas rosiglitazone treatment in obese iNOS-/- markedly enhanced the ability of insulin to phosphorylate the enzyme (Fig. 3B). Similar data were obtained when assessing more proximal insulin-signaling events, such as insulin-induced p85 binding to tyrosine-phosphorylated IRS-1/2 in muscle and liver and IRS-2 tyrosine phosphorylation in liver (Supplementary Fig. 1, which is detailed in the online appendix [available at ]).
###end p 46
###begin title 47
###xml 99 103 <span type="species:ncbi:10090">mice</span>
iNOS disruption increases the ability of rosiglitazone to raise plasma adiponectin levels in obese mice.
###end title 47
###begin p 48
###xml 125 126 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 127 128 127 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 294 295 294 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 288 295 288 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 397 400 397 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 435 438 435 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 640 643 640 643 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 671 674 671 674 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 948 949 948 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 270 274 <span type="species:ncbi:10090">mice</span>
###xml 439 443 <span type="species:ncbi:10090">mice</span>
###xml 520 524 <span type="species:ncbi:10090">mice</span>
###xml 644 648 <span type="species:ncbi:10090">mice</span>
###xml 675 679 <span type="species:ncbi:10090">mice</span>
Thiazolidinediones are known to exert their beneficial effects largely by increasing adiponectin circulating concentrations (4,6). We thus next examined whether iNOS disruption modulates the ability of rosiglitazone to increase plasma adiponectin concentration in obese mice. As shown in Fig. 4A, rosiglitazone treatment induced a 2.9-fold increase in total plasma adiponectin levels in obese iNOS+/+ compared with untreated obese iNOS+/+ mice. A similar effect of the thiazolidinedione was observed in chow-fed control mice (data not shown). Remarkably, the effect of rosiglitazone on adiponectin levels was markedly enhanced in obese iNOS-/- mice relative to obese iNOS+/+ mice, as reflected by the 5.6-fold increase in the adipokine plasma concentrations after thiazolidinedione treatment in the former group. Resistin plasma levels were also measured but found not to be affected by the genotype or rosiglitazone treatment (Supplementary Fig. 2A).
###end p 48
###begin p 49
###xml 150 151 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 444 445 444 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 438 445 438 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 533 536 533 536 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 597 600 597 600 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 432 436 <span type="species:ncbi:10090">mice</span>
###xml 537 541 <span type="species:ncbi:10090">mice</span>
###xml 601 605 <span type="species:ncbi:10090">mice</span>
###xml 680 684 <span type="species:ncbi:10090">mice</span>
Because complex distribution, not the absolute amounts of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity (7), we next evaluated the effect of rosiglitazone on the formation of high-molecular weight complexes of adiponectin in wild-type and iNOS-deficient animals. Obesity in both genotypes had no effect on basal high-molecular weight adiponectin plasma levels compared with lean control mice (Fig. 4A, dashed line). Rosiglitazone barely increased high-molecular weight adiponectin in iNOS+/+ mice, but the thiazolidinedione was much more potent in iNOS-/- mice, increasing high-molecular weight adiponectin levels by 8.2-fold in these mice.
###end p 49
###begin title 50
###xml 57 61 <span type="species:ncbi:10090">mice</span>
Rosiglitazone induces adipose tissue remodeling in obese mice lacking iNOS.
###end title 50
###begin p 51
###xml 340 343 340 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 356 357 356 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 350 357 350 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 457 460 457 460 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 537 538 537 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 565 566 565 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 620 623 620 623 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 344 348 <span type="species:ncbi:10090">mice</span>
###xml 461 465 <span type="species:ncbi:10090">mice</span>
###xml 624 628 <span type="species:ncbi:10090">mice</span>
Because adiponectin secretion is greater in newly differentiated small adipocytes, we next explored the possibility that rosiglitazone exerted a genotype-specific effect on adipose tissue remodeling. Histological analysis showed that rosiglitazone, at the low dose used, failed to significantly affect adipocyte size or number in obese iNOS+/+ mice (Fig. 4B). In marked contrast, the thiazolidinedione clearly induced adipose tissue remodeling in obese iNOS-/- mice, which was characterized by the presence of an increased number (+75%, P < 0.05) of smaller (-45%, P < 0.05) adipocytes compared with untreated obese iNOS-/- mice.
###end p 51
###begin p 52
###xml 123 124 119 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 129 130 125 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 323 326 311 314 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 222 226 <span type="species:ncbi:10090">mice</span>
###xml 327 331 <span type="species:ncbi:10090">mice</span>
Adipose tissue levels of both TNF-alpha and IL-6 were increased by high-fat feeding in both genotypes (Supplementary Fig. 2B and C). Moreover, TNF-alpha was slightly increased by rosiglitazone treatment in obese wild-type mice. Interestingly, the effect of rosiglitazone on adipose TNF-alpha levels was not observed in iNOS-/- mice, suggesting that iNOS may be needed for this action. No effect of the genotype was observed on adipose IL-6 levels.
###end p 52
###begin title 53
###xml 84 87 84 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 88 92 <span type="species:ncbi:10090">mice</span>
Increased AMPK activation and energy expenditure in rosiglitazone-treated obese iNOS-/- mice.
###end title 53
###begin p 54
###xml 55 57 55 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 58 60 58 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 364 365 364 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 366 367 366 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 358 367 358 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic>&#8211;<italic>C</italic></xref>
###xml 477 480 477 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 518 521 518 521 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 534 535 534 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 536 537 536 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 528 537 528 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic>&#8211;<italic>C</italic></xref>
###xml 613 616 613 616 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 981 984 981 984 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1121 1123 1121 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 1313 1316 1313 1316 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1422 1423 1422 1423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1416 1423 1416 1423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>D</italic></xref>
###xml 1485 1488 1485 1488 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1503 1506 1503 1506 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1582 1585 1582 1585 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1710 1713 1710 1713 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1729 1730 1729 1730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1723 1730 1723 1730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>D</italic></xref>
###xml 481 485 <span type="species:ncbi:10090">mice</span>
###xml 522 526 <span type="species:ncbi:10090">mice</span>
###xml 617 621 <span type="species:ncbi:10090">mice</span>
###xml 785 789 <span type="species:ncbi:10090">mice</span>
###xml 1115 1119 <span type="species:ncbi:10116">rats</span>
###xml 1507 1511 <span type="species:ncbi:10090">mice</span>
###xml 1586 1590 <span type="species:ncbi:10090">mice</span>
###xml 1888 1892 <span type="species:ncbi:10090">mice</span>
Because adiponectin activates AMPK in several tissues (32,33), we next determined whether elevation of circulating adiponectin in response to rosiglitazone is associated with AMPK activation in insulin-target tissues. Both phosphorylation of AMPK on Thr172 and of ACC on Ser-79, a well-established downstream target of AMPK activation (34), were determined (Fig. 5A-C). Activation of the AMPK pathway was found to be reduced in muscle, liver, and WAT of high-fat-fed obese iNOS+/+ mice compared with lean chow-fed iNOS+/+ mice (Fig. 5A-C, dashed lines). At the low dose used, rosiglitazone treatment of obese iNOS+/+ mice improved ACC phosphorylation in WAT but not in muscle and liver. However, the thiazolidinedione markedly improved ACC phosphorylation in muscle, liver, and WAT of mice lacking iNOS. Interestingly, the enhanced ACC phosphorylation in both liver and fat (but not in muscle) was at least partly accounted for by an increased expression of ACC, especially in iNOS-/- tissues. This effect of rosiglitazone to increase ACC protein levels has been recently reported in adipose tissue of high-fat-fed rats (35). Because AMPK activation switches on catabolic pathways and increases energy expenditure, we next determined whether enhanced activation of this pathway in rosiglitazone-treated obese iNOS-/- led to increased whole-body energy expenditure as measured by indirect calorimetry. As depicted in Fig. 5D, total energy expenditure was similar in untreated obese iNOS+/+ and obese iNOS-/- mice. However, energy expenditure was significantly increased in obese iNOS-/- mice treated with rosiglitazone. The respiratory quotient was reduced in all high-fat-fed groups compared with chow-fed iNOS+/+ animals (Fig. 5D), consistent with increased consumption of dietary lipids. On the other hand, neither iNOS gene disruption nor rosiglitazone treatment of high-fat-fed obese mice affected the respiratory quotient, indicating that fat remained the principal substrate source in all groups consuming the high-fat diet.
###end p 54
###begin title 55
iNOS inhibits PPAR-gamma activity in adipose tissue and adipocytes.
###end title 55
###begin p 56
###xml 207 210 199 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 256 263 248 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6A</xref>
###xml 450 452 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 453 455 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 655 658 635 638 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 682 685 662 665 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1253 1254 1213 1214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1247 1254 1207 1214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>B</italic></xref>
###xml 1932 1933 1860 1861 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1926 1933 1854 1861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>C</italic></xref>
###xml 2136 2137 2060 2061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 2130 2137 2054 2061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>D</italic></xref>
###xml 48 52 <span type="species:ncbi:10090">mice</span>
###xml 211 215 <span type="species:ncbi:10090">mice</span>
###xml 324 328 <span type="species:ncbi:10090">mice</span>
###xml 659 663 <span type="species:ncbi:10090">mice</span>
Because rosiglitazone action was potentiated in mice with iNOS gene disruption, we next tested whether PPAR-gamma activation was affected by the genotype. PPAR-gamma expression was increased in chow-fed iNOS-/- mice compared with their wild-type controls (Fig. 6A). This genotype effect was not observed in the high-fat-fed mice. We also assessed PPAR-gamma phosphorylation on Ser-82/112, which is associated with decreased transcriptional activity (36,37). We found that PPAR-gamma phosphorylation on Ser-82/112, corrected for the PPAR-gamma protein abundance in the sample, was significantly reduced in adipose tissue of both chow- and high-fat-fed iNOS-/- mice compared with iNOS+/+ counterparts. This effect was similar for PPAR-gamma1 (Ser-82) and PPAR-gamma2 (Ser-112) isoforms, which are both expressed in adipose tissue. This suggests that lack of iNOS increases PPAR-gamma transcriptional activity in adipose tissue. To more directly test this hypothesis, we next determined the effect of NO on PPAR-gamma in cultured adipocytes. Differentiated 3T3-L1 adipocytes were exposed to increasing concentrations of the NO donor sodium nitroprusside for 24 h, and PPAR-gamma expression and phosphorylation were assessed by Western blot analysis (Fig. 6B). These experiments revealed that sodium nitroprusside reduces the expression of PPAR-gamma (both gamma1 and gamma2 isoforms). Furthermore, the ratio of Ser-82/112 phosphorylated PPAR-gamma over total PPAR-gamma protein was increased, suggesting that sodium nitroprusside blunts PPAR-gamma transcriptional activity both by lowering its expression and increasing its inhibitory phosphorylation. Interestingly, these effects were not observed on exposing cells to the NO derivative peroxynitrite. To more directly test whether NO inhibits PPAR-gamma transcriptional activity, we prepared nuclear extracts from these cells to assess PPAR-gamma transcription factor binding (Fig. 6C). We also transfected HEK293T cells with a PPAR-gamma reporter (pGL3-PPRE) and looked at its troglitazone-induced activity after treatment with the NO donor sodium nitroprusside or peroxynitrite (Fig. 6D). These experiments revealed that sodium nitroprusside causes a dose-dependent inhibition of both PPAR-gamma binding and thiazolidinedione-induced activity, confirming that NO but not peroxynitrite blunts PPAR-gamma transcriptional activity in adipocytes.
###end p 56
###begin title 57
DISCUSSION
###end title 57
###begin p 58
###xml 511 513 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 514 516 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 646 648 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
PPAR-gamma agonists, such as thiazolidinediones, are known for their antidiabetic and insulin-sensitizing properties. Rosiglitazone and pioglitazone are two clinically approved thiazolidinediones for the management of obesity-linked type 2 diabetes, but some side effects are associated with their use. Treatment with thiazolidinediones is usually correlated with increased body weight gain due to differentiation of fat cells and fluid retention caused by accelerated sodium absorption by the collecting duct (38,39). Thiazolidinedione treatment has also been recently associated with increased risk for myocardial infarction and heart failure (40). This prompts the elaboration of new PPAR-gamma agonists and the search for novel PPAR-gamma regulatory pathways. Here, we show that the iNOS/NO pathway is a novel and critical modulator of thiazolidinedione/PPAR-gamma action in an animal model of obesity.
###end p 58
###begin p 59
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r44">44</xref>
###xml 933 935 933 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r45">45</xref>
###xml 1268 1270 1256 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r46">46</xref>
###xml 1360 1362 1344 1346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r47">47</xref>
###xml 1463 1465 1447 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r48">48</xref>
###xml 1654 1656 1634 1636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r49">49</xref>
###xml 1657 1659 1637 1639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r50">50</xref>
###xml 2321 2323 2297 2299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r51">51</xref>
###xml 228 232 <span type="species:ncbi:10090">mice</span>
###xml 701 705 <span type="species:ncbi:10090">mice</span>
###xml 1389 1393 <span type="species:ncbi:10090">mice</span>
###xml 1986 1990 <span type="species:ncbi:10090">mice</span>
###xml 2204 2208 <span type="species:ncbi:10090">mice</span>
To demonstrate the involvement of the iNOS/NO pathway in thiazolidinedione action in vivo, we compared the action of a low dose of rosiglitazone on several glucoregulatory and metabolic parameters in wild-type and iNOS knockout mice rendered obese by feeding a high-fat diet. A relatively low dose of rosiglitazone (0.1 vs. 0.4-3 mg/day in most studies [41-44]) and a short duration of treatment were used to better appreciate the effect of the absence of iNOS on the metabolic actions of thiazolidinedione. We found that this low dose of rosiglitazone improves insulin sensitivity and insulin signaling in muscle but failed to improve glucose tolerance and liver insulin signaling in wild-type obese mice. This is consistent with previous observations showing that muscle insulin sensitivity is rapidly improved by thiazolidinediones, whereas a longer duration of treatment is generally required to improve insulin action in liver (45). Recent studies using tissue-specific disruption of PPAR-gamma have dissected out the contribution of the principal PPAR-gamma-expressing tissues to action of thiazolidinedione. Muscle PPAR-gamma plays a crucial role in maintaining systemic insulin sensitivity and in mediating thiazolidinedione action in muscle but not in liver (46). In contrast, liver PPAR-gamma expression is not required for thiazolidinedione action (47), but studies using A-Zip mice lacking adipose tissue showed thiazolidinedione resistance in liver (48). Taken together, these studies suggest that the beneficial effects of thiazolidinedione on the liver are most likely mediated by adipose tissue, which predominantly expresses PPAR-gamma (49,50). In agreement with these observations, the lack of significant effect of a low dose of rosiglitazone on liver insulin signaling and glucose tolerance in the present study was associated with failure of the thiazolidinedione to change adipose tissue morphology. In sharp contrast, iNOS disruption was found to sensitize obese mice to the action of rosiglitazone on glucose tolerance and liver insulin action without any further effect in muscle. This genotype-specific action of thiazolidinedione was linked to fat remodeling in iNOS-deficient mice as revealed by increased adipose tissue cellularity, an established indicator of adipose PPAR-gamma activation (51).
###end p 59
###begin p 60
###xml 105 106 101 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 441 442 429 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 634 639 622 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ob/ob</italic>
###xml 777 778 765 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 938 939 926 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 940 941 928 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 1426 1427 1414 1415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 1724 1726 1712 1714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r52">52</xref>
###xml 1727 1729 1715 1717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r53">53</xref>
###xml 567 571 <span type="species:ncbi:10090">mice</span>
###xml 640 644 <span type="species:ncbi:10090">mice</span>
###xml 771 775 <span type="species:ncbi:10090">mice</span>
###xml 1082 1086 <span type="species:ncbi:10090">mice</span>
###xml 1129 1133 <span type="species:ncbi:10090">mice</span>
###xml 1507 1511 <span type="species:ncbi:10090">mice</span>
It is well known that PPAR-gamma agonists increase total plasma adiponectin levels by two- to threefold (3). Adiponectin is thought to be the principal mediator of the insulin-sensitizing action of PPAR-gamma. Transgene-induced overexpression of adiponectin, which raises the secretion of the adipokine in its native oligomeric form by threefold, was found to induce effects similar to those of a chronic treatment with PPAR-gamma agonists (4). More direct evidence for the role of adiponectin in thiazolidinedione action was recently provided using adiponectin-null mice. The ability of rosiglitazone to improve glucose tolerance in ob/ob mice lacking adiponectin is markedly diminished. Furthermore, rosiglitazone failed to activate AMPK in tissues of adiponectin-null mice (6). Moreover, it has been shown that the high-molecular weight complex structure of adiponectin is key to its insulin-sensitizing action, particularly in liver (7,8). These studies showed that only high-molecular weight adiponectin can reduce blood glucose levels when injected into adiponectin-deficient mice. Consistent with these observations, only mice lacking iNOS, which showed a marked elevation in plasma high-molecular weight adiponectin levels, exhibited improved glucose tolerance and liver insulin action in response to rosiglitazone, confirming the high sensitivity of the liver to changes in high-molecular weight form concentrations (7). Adipose tissue remodeling caused by rosiglitazone treatment of iNOS knockout mice likely explains the raised plasma high-molecular weight adiponectin complexes in these animals because previous studies reported a strong inverse relationship between adipose cell size and adiponectin secretion (52,53).
###end p 60
###begin p 61
###xml 371 373 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 374 376 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 547 549 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r54">54</xref>
###xml 792 798 788 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 1194 1197 1190 1193 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1206 1209 1202 1205 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1367 1370 1363 1366 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
###xml 523 527 <span type="species:ncbi:10090">mice</span>
###xml 841 845 <span type="species:ncbi:10090">mice</span>
###xml 1371 1375 <span type="species:ncbi:10090">mice</span>
###xml 1493 1497 <span type="species:ncbi:10090">mice</span>
Rosiglitazone treatment increased AMPK activity in fat but not in muscle and liver of wild-type obese mice, even though the PPAR-gamma agonist induced a threefold increase in plasma adiponectin levels. At first sight, this may appear surprising because activation of AMPK by adiponectin is thought to be involved in its glucose metabolic and insulin-sensitizing actions (32,33). However, this may be explained by the failure of rosiglitazone to raise plasma adiponectin in its high-molecular weight form in wild-type obese mice. Kobayashi et al. (54) showed that only the high-molecular weight complex of adiponectin can activate AMPK in endothelial cells. The lack of effect of rosiglitazone on high-molecular weight adiponectin secretion could be linked to iNOS induction in these animals (Fig. 1). We propose that in iNOS-deficient obese mice, the effects of rosiglitazone on high-molecular weight adiponectin secretion and AMPK activation are unopposed by iNOS-derived NO, resulting in improved metabolic actions, as reflected by enhanced energy expenditure and decreased levels of plasma triglycerides. The finding of unaltered respiratory quotient values among the high-fat-fed obese iNOS+/+ and iNOS-/- groups probably reflects the fact that both fat and glucose oxidation are expected to be increased on marked activation of AMPK in rosiglitazone-treated iNOS-/- mice. Hence, our data are consistent with the hypothesis that induction of the iNOS/NO pathway in adipose tissue of obese mice contributes to deteriorating hepatic insulin action and glucose tolerance by interfering with the ability of rosiglitazone to increase plasma high-molecular weight adiponectin and liver AMPK activation.
###end p 61
###begin p 62
###xml 239 241 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 242 244 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 353 356 341 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
###xml 776 780 <span type="species:ncbi:10090">mice</span>
###xml 889 893 <span type="species:ncbi:10090">mice</span>
We further explored whether the iNOS/NO pathway blunts the action of thiazolidinedione by interfering with PPAR-gamma transcriptional activity. Phosphorylation of PPAR-gamma on Ser-82/112 is known to suppress its transcriptional activity (36,37). Inhibitory phosphorylation of both PPAR-gamma isoforms on Ser-82/112 was reduced in adipose tissue of iNOS-/- mice, whereas treatment of adipocytes with the NO donor sodium nitroprusside enhanced PPAR-gamma Ser-82/112 phosphorylation and blunted thiazolidinedione-induced PPAR-gamma reporter activity, consistent with the hypothesis that iNOS-derived NO represses PPAR-gamma transcriptional activity. Our data further suggest that iNOS represses adipose PPAR-gamma expression. This finding was not observed in high-fat-fed obese mice lacking iNOS, suggesting that other factors than NO may repress PPAR-gamma in adipose tissue of these obese mice.
###end p 62
###begin p 63
###xml 129 130 129 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
NO exerts its action in part by inducing posttranslational modifications of specific amino acid residues within target proteins. S-nitrosylation of cysteine residues within signaling proteins occurs in physiological conditions, whereas tyrosine nitration is typically associated with increased generation of the NO derivative peroxynitrite in oxidative stress-related diseases. Shibuya et al. (28) previously reported that treatment of macrophages with inflammatory cytokines, LPS, or peroxynitrite increased tyrosine nitration of PPAR-gamma, resulting in impaired ligand-dependent nuclear translocation. However, peroxynitrite failed to reduce PPAR-gamma transcriptional activity in our adipocyte studies, suggesting that PPAR-gamma regulation may be differently controlled in adipose versus myeloid cells. Further studies will be required to identify the mechanism(s) by which NO suppresses PPAR-gamma activity.
###end p 63
###begin p 64
###xml 117 119 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 540 542 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r55">55</xref>
###xml 543 545 531 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r56">56</xref>
###xml 809 811 793 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r57">57</xref>
###xml 270 274 <span type="species:ncbi:10090">mice</span>
###xml 608 612 <span type="species:ncbi:10090">mice</span>
###xml 905 909 <span type="species:ncbi:10090">mice</span>
###xml 1271 1275 <span type="species:ncbi:10090">mice</span>
###xml 1327 1331 <span type="species:ncbi:10090">mice</span>
We have reported that iNOS induction is repressed after AMPK activation by PPAR-gamma agonists in 3T3-L1 adipocytes (17). The present study confirms that this inhibitory effect of PPAR-gamma on iNOS induction also occurs in fat tissue of thiazolidinedione-treated obese mice. We hypothesize that the inhibitory effect of rosiglitazone treatment on iNOS induction may be linked to its ability to raise adiponectin levels because the adipokine suppresses cytokine production and NF-kappaB transcriptional activation by activated macrophages (55,56). However, we found that rosiglitazone treatment of wild-type mice, despite raising adiponectin levels, failed to reduce IL-6 and in fact slightly increased TNF-alpha levels in adipose tissue. This intriguing effect of rosiglitazone has been reported previously (57). Interestingly, rosiglitazone failed to increase adipose TNF-alpha levels in iNOS-deficient mice, possibly because the drug further raised plasma adiponectin concentrations, particularly in its high-molecular weight form, thus blunting rosiglitazone effect on TNF-alpha in the latter genotype. Thus, iNOS inhibition by PPAR-gamma activation is a key anti-inflammatory mechanism that likely contributes to the beneficial effects of thiazolidinedione in obese mice. This is exemplified by our data in iNOS-deficient mice where complete lack of iNOS was found to markedly sensitize PPAR-gamma agonism in WAT, as reflected by adipose tissue histology and adiponectin secretion, particularly in its high-molecular weight form.
###end p 64
###begin p 65
###xml 215 221 211 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f7" ref-type="fig">Fig. 7</xref>
###xml 347 349 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 801 803 789 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 1077 1080 1061 1064 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1081 1085 <span type="species:ncbi:10090">mice</span>
Taken together, our results allow the design of a model that integrates the metabolic and anti-inflammatory effects of thiazolidinedione in obesity, emphasizing the roles of PPAR-gamma, iNOS, adiponectin, and AMPK (Fig. 7). iNOS is induced in obesity, which leads to the development of inflammation-mediated insulin resistance in skeletal muscle (18) and reduced action of PPAR-gamma ligands in adipose tissue. The latter results in reduced adiponectin secretion, particularly in its high-molecular weight form, and limited activation of AMPK and tissue insulin signaling, particularly in the liver. Thiazolidinedione increase muscle insulin action by directly targeting muscle PPAR-gamma. Lack of iNOS improved insulin sensitivity in muscle but had no effect on the liver, as we previously reported (18). However, iNOS disruption sensitizes adipose tissue to PPAR-gamma agonism, thus raising plasma high-molecular weight adiponectin levels. This leads to increased AMPK activation in the liver and improvement of hepatic insulin sensitivity and glucose tolerance in obese iNOS-/- mice.
###end p 65
###begin p 66
###xml 683 685 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r58">58</xref>
The present results have potential clinical relevance. iNOS might represent a promising therapeutic target to increase PPAR-gamma agonism in obese insulin-resistant subjects, reducing the effective doses of thiazolidinediones for improving glucose tolerance. By increasing the efficacy of thiazolidinediones, iNOS inhibitors might limit the side effects of these drugs on the renal and cardiovascular systems. It has been reported that the endothelial hyperpermeability response to rosiglitazone was most pronounced at concentrations of the thiazolidinedione (10-100 mumol/l) that correspond to the upper range of therapeutic plasma drug concentrations in routine clinical practice (58). Thus, combination therapy with a low dose of thiazolidinedione and iNOS inhibitors may represent a promising avenue for the treatment of obesity-linked type 2 diabetes.
###end p 66
###begin title 67
Supplementary Material
###end title 67
###begin title 68
Online-Only Appendix
###end title 68
###begin p 69
P.D. has received a studentship from the Canadian Diabetes Association and the Canadian Institutes of Health Research (CIHR). K.B. has received a fellowship from Merck Frosst. P.P. has received a studentship from CIHR. M.E.T. has received a fellowship from the American Diabetes Association. P.E.S. has received National Institutes of Health Grants R01-DK-55758 and R01-CA-112023 and an Irma T. Hirschl Career Scientist Award. M.P. has received a grant from the CIHR. A.M. has received a grant from the CIHR and a CIHR Investigator Award and currently holds a National Researcher Career Award from the Fonds de la Recherche en Sante du Quebec.
###end p 69
###begin p 70
We thank Genevieve Pilon for her contribution to the design of many experiments and Luce Dombrowski and Natalie Lefort for technical assistance. We also thank Drs. F. Picard and J. Lavoie for providing cells and plasmids.
###end p 70
###begin title 71
REFERENCES
###end title 71
###begin p 72
###xml 78 79 78 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 94 95 94 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 202 205 202 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 214 217 214 217 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 254 257 254 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 423 424 418 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 459 462 454 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 465 466 460 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 529 530 513 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 557 560 541 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 61 65 <span type="species:ncbi:10090">mice</span>
###xml 218 222 <span type="species:ncbi:10090">mice</span>
###xml 258 262 <span type="species:ncbi:10090">mice</span>
###xml 308 312 <span type="species:ncbi:10090">mice</span>
###xml 511 515 <span type="species:ncbi:10090">mice</span>
###xml 561 565 <span type="species:ncbi:10090">mice</span>
Rosiglitazone reduces iNOS expression in WAT of high-fat-fed mice. iNOS mRNA (A) and protein (B) expression was evaluated by semiquantitative RT-PCR and Western blotting in WAT of high-fat (HF)-fed iNOS+/+ and iNOS-/- mice and compared with chow-fed iNOS+/+ mice. Each bar represents the mean +/- SE of 6-10 mice. Data are expressed as the ratio of iNOS over beta-actin mRNA levels or as arbitrary units for iNOS protein. *P < 0.05 vs. untreated chow-fed iNOS+/+, #P < 0.05 vs. respective rosiglitazone-treated mice, section signP < 0.05 vs. respective iNOS+/+ mice.
###end p 72
###begin p 73
###xml 185 186 185 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 191 192 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 206 207 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 208 209 208 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 231 232 231 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 233 234 233 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 255 256 255 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 348 351 348 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 358 359 358 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 495 496 495 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 515 516 515 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 545 546 545 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 575 576 575 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 620 621 620 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 828 829 826 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 831 832 829 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 838 839 836 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 842 843 840 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 893 896 891 894 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 902 903 900 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 908 909 906 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 912 913 910 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 942 943 940 941 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 959 962 957 960 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 979 980 972 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1019 1022 1012 1015 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1029 1030 1022 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1033 1034 1026 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1069 1072 1062 1065 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 101 105 <span type="species:ncbi:10090">mice</span>
###xml 124 128 <span type="species:ncbi:10090">mice</span>
###xml 352 356 <span type="species:ncbi:10090">mice</span>
###xml 726 730 <span type="species:ncbi:10090">mice</span>
###xml 802 806 <span type="species:ncbi:10090">mice</span>
###xml 896 900 <span type="species:ncbi:10090">mice</span>
###xml 935 939 <span type="species:ncbi:10090">mice</span>
###xml 963 967 <span type="species:ncbi:10090">mice</span>
###xml 1023 1027 <span type="species:ncbi:10090">mice</span>
###xml 1073 1077 <span type="species:ncbi:10090">mice</span>
Effect of iNOS gene disruption on the glucoregulatory effects of rosiglitazone in high-fat-fed obese mice. Five-hour-fasted mice were acutely injected (intraperitoneally) with insulin (A and B) or glucose (C-E), and blood glucose (A-D) or plasma insulin (E) was measured at indicated times. Dashed lines represent values for untreated chow-fed iNOS+/+ mice. A: Insulin tolerance test (ITT) was performed for 60 min, and relative blood glucose values at time 15 min were compared between groups (B). Glucose curves (C) and area under the curves (D) of a 90-min GTT are shown. E: Plasma insulin concentrations during GTT. F: Glucose-stimulated insulin release was measured in vitro using freshly isolated islets from 5-h-fasted mice at 3, 8, and 16 mmol/l glucose (3G, 8G, and 16G). Means +/- SE of 6-10 mice per group are shown. A, C, and E: *P < 0.05 vs. respective untreated high-fat-fed iNOS+/+mice. B and D: *P < 0.05 vs. untreated mice, #P < 0.05 vs. iNOS+/+ mice, and daggerP < 0.05 vs. untreated high-fat-fed iNOS+/+ mice. F: #P < 0.05 vs. untreated chow-fed iNOS+/+ mice.
###end p 73
###begin p 74
###xml 340 341 309 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 354 355 323 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 467 470 436 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 605 608 574 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 673 674 629 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 710 711 666 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 740 741 696 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 757 760 713 716 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 773 774 724 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 813 816 764 767 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 133 137 <span type="species:ncbi:10090">mice</span>
###xml 139 143 <span type="species:ncbi:10090">Mice</span>
###xml 471 475 <span type="species:ncbi:10090">mice</span>
###xml 609 613 <span type="species:ncbi:10090">mice</span>
###xml 635 639 <span type="species:ncbi:10090">mice</span>
###xml 703 707 <span type="species:ncbi:10090">mice</span>
###xml 733 737 <span type="species:ncbi:10090">mice</span>
###xml 761 765 <span type="species:ncbi:10090">mice</span>
###xml 817 821 <span type="species:ncbi:10090">mice</span>
Effect of iNOS gene disruption and rosiglitazone on insulin-stimulated Akt phosphorylation in muscle and liver of high-fat-fed obese mice. Mice were acutely injected (intravenously) with saline (square) or 3.8 units/kg insulin (blacksquare, square, filled). Akt Ser phosphorylation was evaluated 4 min after injection in quadriceps muscle (A) and liver (B) by Western blot. Data are expressed relative to the mean values of insulin-stimulated, untreated chow-fed iNOS+/+ mice (upper dashed line) loaded on the same gel. The lower dashed line represents basal Akt phosphorylation in untreated chow-fed iNOS+/+ mice. Means +/- SE of 3-5 mice per group are shown. section signP < 0.05 vs. insulin-injected mice, *P < 0.05 vs. untreated mice, #P < 0.05 vs. iNOS+/+ mice, daggerP < 0.05 vs. untreated high-fat-fed iNOS+/+ mice.
###end p 74
###begin p 75
###xml 139 140 139 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 500 503 469 472 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 510 511 479 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 680 681 647 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 710 711 677 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 727 730 694 697 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 133 137 <span type="species:ncbi:10090">mice</span>
###xml 504 508 <span type="species:ncbi:10090">mice</span>
###xml 663 667 <span type="species:ncbi:10090">mice</span>
###xml 703 707 <span type="species:ncbi:10090">mice</span>
###xml 731 735 <span type="species:ncbi:10090">mice</span>
Effect of iNOS gene disruption and rosiglitazone treatment on plasma adiponectin and adipose tissue remodeling in high-fat-fed obese mice. A: Total adiponectin concentrations (square) and high-molecular weight adiponectin complexes (HMW, blacksquare, square, filled) were measured in plasma by radioimmunoassay and size fractionation followed by quantitative Western blotting, respectively. The dotted lines corresponds to total and high-molecular weight adiponectin levels in untreated chow-fed iNOS+/+ mice. B: Histological analysis of WAT of high-fat-fed animals. Mean weight and cell number per fat pad are also shown. Bars represent the means +/- SE of 5-16 mice per group. *P < 0.05 vs. untreated mice, #P < 0.05 vs. iNOS+/+ mice.
###end p 75
###begin p 76
###xml 246 247 246 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 257 258 257 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 270 271 270 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 348 351 348 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 406 407 406 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 440 443 440 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 471 477 471 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 555 556 553 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 596 597 594 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 624 627 622 625 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 640 641 633 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 680 683 673 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 117 121 <span type="species:ncbi:10090">mice</span>
###xml 352 356 <span type="species:ncbi:10090">mice</span>
###xml 538 542 <span type="species:ncbi:10090">mice</span>
###xml 589 593 <span type="species:ncbi:10090">mice</span>
###xml 628 632 <span type="species:ncbi:10090">mice</span>
###xml 684 688 <span type="species:ncbi:10090">mice</span>
Effect of iNOS gene disruption and rosiglitazone treatment on AMPK activation and energy expenditure in high-fat-fed mice. Phosphorylation of AMP-activated kinase (P-AMPK) and ACC (P-ACC) and total expression were evaluated in quadriceps muscle (A), liver (B), and WAT (C) by Western blotting. Data are expressed relative to untreated chow-fed iNOS+/+ mice values (dashed lines) analyzed on the same gels. D: Whole-body energy expenditure (top) and respiratory quotient (bottom) were measured by indirect calorimetry. Means +/- SE of 4-8 mice per group. *P < 0.05 vs. respective untreated mice, #P < 0.05 vs. respective iNOS+/+ mice, daggerP < 0.05 vs. untreated high-fat-fed iNOS+/+ mice.
###end p 76
###begin p 77
###xml 54 55 50 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 265 266 255 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 280 281 270 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 316 317 306 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 344 347 334 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 360 361 345 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 400 403 385 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 410 411 395 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 416 417 401 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 561 562 546 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 717 718 698 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 791 818 768 795 <sc xmlns:xlink="http://www.w3.org/1999/xlink">research design and methods</sc>
###xml 898 899 873 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 932 933 907 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1251 1252 1219 1220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1263 1264 1231 1232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1297 1298 1265 1266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1303 1304 1271 1272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 309 313 <span type="species:ncbi:10090">mice</span>
###xml 348 352 <span type="species:ncbi:10090">mice</span>
###xml 404 408 <span type="species:ncbi:10090">mice</span>
The iNOS/NO pathway suppresses PPAR-gamma activation. A: WAT extracts were analyzed by immunoblotting for PPAR-gamma expression and phosphorylation on Ser-82/112 and for tubulin expression. Shown are representative gels and means +/- SE of five animals per group. *P < 0.05 or ***P < 0.001 vs. wild-type chow mice. #P < 0.05 vs. respective iNOS+/+ mice, daggerP < 0.05 vs. untreated high-fat-fed iNOS+/+ mice. B and C: Differentiated 3T3-L1 adipocytes were treated with sodium nitroprusside (SNP) or peroxynitrite (PN) at the indicated concentrations for 24 h. B: Total cellular extracts were analyzed by Western blot for the expression of PPAR-gamma and its phosphorylation on Ser-82/112, as well as tubulin levels. C: Nuclear extracts were analyzed for PPAR-gamma activity as described in research design and methods. Shown are means +/- SE of four determinations in two individual experiments; *P < 0.05 vs. control (CTL) cells. D: Luciferase assays of 293T cells transfected with PPAR-gamma2 and pGL3-PPRE and treated with sodium nitroprusside or peroxynitrite at the indicated concentration for 24 h. During the last 16 h of treatment, 20 mumol/l troglitazone was added. Shown are means +/- SE of four individual experiments done in triplicate; *P < 0.05, **P < 0.01 vs. control (CTL) cells. C and D: Supernatants were sampled for nitrite determinations, and values are shown under the graphs.
###end p 77
###begin p 78
###xml 130 131 126 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 150 153 146 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 437 439 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 526 529 514 517 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 605 606 593 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 629 632 617 620 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 154 158 <span type="species:ncbi:10090">mice</span>
###xml 431 435 <span type="species:ncbi:10090">mice</span>
###xml 530 534 <span type="species:ncbi:10090">mice</span>
###xml 692 696 <span type="species:ncbi:10090">mice</span>
Proposed model by which iNOS induction in obesity modulates thiazolidinedione (TZD)/PPAR-gamma agonism in insulin-target tissues. A: In wild-type iNOS+/+ mice, obesity leads to iNOS induction in fat and muscle, which contributes to promote insulin resistance in muscle and impairs PPAR-gamma action in adipose tissue. Obesity also impairs hepatic insulin action even if iNOS is not induced, as shown in liver of high-fat-fed obese mice (18). PPAR-gamma agonists, such as thiazolidinediones, reduce iNOS induction in obese iNOS+/+ mice, leading to improvement in insulin action in muscle but not in liver. B: iNOS disruption (iNOS-/-) increases muscle insulin action but also sensitizes obese mice to the effect of PPAR-gamma ligands on adipose tissue, leading to an increased number of smaller adipocytes and enhanced secretion of adiponectin, particularly in its high-molecular weight complex form. Elevated high-molecular weight adiponectin mainly targets the liver through AMPK activation, resulting in increased hepatic insulin action and improved glucose tolerance.
###end p 78
###begin p 79
###xml 32 35 32 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 44 47 44 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 48 52 <span type="species:ncbi:10090">mice</span>
Physiological parameters of iNOS+/+ and iNOS-/- mice fed chow or high-fat diet and treated or not with rosiglitazone
###end p 79
###begin p 80
Data are means +/- SE.
###end p 80
###begin p 81
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 28 31 28 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 32 36 <span type="species:ncbi:10090">mice</span>
P < 0.05 vs. respective iNOS+/+ mice,
###end p 81
###begin p 82
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 43 46 43 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
P < 0.05 vs. respective diet untreated iNOS+/+ mice (ANOVA followed by Fisher's post hoc test),
###end p 82
###begin p 83
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 34 38 <span type="species:ncbi:10090">mice</span>
P < 0.05 vs. respective untreated mice.
###end p 83

